Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
The medicine was well tolerated, with no unexpected safety issue
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
This year’s edition will witness participation of over 700 Indian exporters showcasing their products and services; 500+ overseas delegates representing more than 120 countries; 20,000 domestic visitors; and 8,000+ B2B meetings
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
Subscribe To Our Newsletter & Stay Updated
